Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies : Episode 9
The Development of Bispecifics-Based Combination Therapies in MM
Dr Maria-Victoria Mateos shares her expert perspectives on current efficacy and safety data on combination strategies with bispecifics in relapsed/refractory MM.
EP: 1.Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab
EP: 2.Selecting Patients with MM for Teclistamab and Optimal Sequencing
EP: 3.Mechanism of Action of Teclistamab in R/R MM and Data Updates
EP: 4.Managing Side Effects of BCMA-Targeting Bispecifics in R/R MM
EP: 5.Bispecific Antibodies in Development for the Treatment of R/R MM
EP: 6.Treatment with Teclistamab Following Progression on CAR-T in R/R MM
EP: 7.Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab
EP: 8.Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics
Now Viewing
EP: 9.The Development of Bispecifics-Based Combination Therapies in MM
EP: 10.Patient Case 3: A 52-Year-Old Treated with a Non-BCMA-Targeting Bispecific
EP: 11.Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM
EP: 12.Recent Data on Non-BCMA Targeting Bispecifics in R/R MM
EP: 13.Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
